Results 231 to 240 of about 1,440,335 (353)

Research Progress on Drug Combination Therapy for Multiple Myeloma [PDF]

Zixi Zhang
openalex   +1 more source

Basilar Artery Occlusion Stroke Managed With Tenecteplase Versus Alteplase Before Endovascular Treatment (BAO‐TNK)

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To compare the effectiveness and safety of tenecteplase (TNK) versus alteplase (TPA) in patients with basilar artery occlusion prior to endovascular treatment (EVT). Methods In this retrospective multicenter study (BAO‐TNK), we analyzed consecutive BAO patients from 14 U.S.
Rahul R. Karamchandani, Dylan N. Wolman, Tyler M. Bielinski, Nitin Goyal, Jeremy B. Rhoten, Mahesh V. Jayaraman, Christian T. Sidebottom, Bradley A. Gross, Alhamza R. Al‐Bayati, Mohamed F. Doheim, Matthew K. Tobin, Anoop Chinthala, Avi Gajjar, Justin Mascitelli, Matthew R. Webb, Jan‐Karl Burkhardt, Kyle W. Scott, Visish Srinivasan, Daniel Tonetti, Manisha Koneru, David J. Altschul, Dhrumhil Vaishnav, Sumeet Multani, Thana Theofanis, William J. Ares, Je Yeong Sone, Ramin Zand, Sasan Bahrami, Jiang Li, Gary Defilipp, Dale Strong, Radmehr Torabi, Krisztina Moldovan, Kelsey E. Kline, Clemens M. Schirmer, Raul G. Nogueira, Alexandra R. Paul, Bradley N. Bohnstedt, Philipp Hendrix   +38 more
wiley   +1 more source

Persistent Leukoencephalopathy Following H1N1 Infection Associated With a Novel MYRF Variant (p.Gly735Asp)

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Mutations in myelin regulatory factor (MYRF) are linked to demyelinating disorders. We report a 38‐year‐old male who developed acute symmetric leukoencephalopathy mimicking a stroke following an influenza A virus infection. While clinical symptoms markedly improved with corticosteroids, MRI revealed persistent white matter lesions, contrasting
Jinghan Hu, Leiyun Huang, Wan Zhu, Min Peng, Qiang Gong, Jing Qian   +5 more
wiley   +1 more source

A COMPARATIVE STUDY ON EFFICACY OF FIXED COMBINATION TIMOLOL/BRINZOLAMIDE VERSUS TRAVOPROST MONO-THERAPY IN DRUG-NAÏVE OPEN-ANGLE GLAUCOMA PATIENTS.

, 2020
Munib Ur Rehman, Shahid Mehmood Diyal, Bilal Humayun Mirza, I. M. Qureshi, Muhammad Rizwan Ullah   +4 more
openalex   +2 more sources

Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin, Hui‐An Lin, Sheng‐Feng Lin   +2 more
wiley   +1 more source

Maintenance therapy after first-line therapy for ovarian cancer: Quantitative effectiveness. [PDF]

CA Cancer J Clin
Campos SM, DiSilvestro J, Blank SV.
europepmc   +1 more source

Multi‐Omics Integration for Advancing Glioma Precision Medicine

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Gliomas are among the most malignant and aggressive tumors of the central nervous system, characterized by the absence of early diagnostic markers, poor prognosis, and a lack of effective treatments. Advances in high‐throughput technologies have facilitated a refined molecular classification of gliomas, incorporating genetic features. However,
Maria Guarnaccia, Valentina La Cognata, Giulia Gentile, Giovanna Morello, Sebastiano Cavallaro   +4 more
wiley   +1 more source

Initial and Programmed Combination Therapy With Oral Drugs for Severe Idiopathic Pulmonary Arterial Hypertension

, 2011
Hisataka Maki, Atsushi Yao, Toshiro Inaba, Taro Shiga, Masaru Hatano, Koichiro Kinugawa, Takeshi Yamashita, Tadanori Aizawa, Ryozo Nagai   +8 more
openalex   +2 more sources

Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer, Frauke Stascheit, Maximilian Mönch, Paolo Doksani, Carla Dusemund, Meret Herdick, Philipp Mergenthaler, Maike Stein, Amani Suboh, Jutta Schröder‐Braunstein, Guido Wabnitz, Jan D. Lünemann, Sophie Lehnerer, Sarah Hoffmann, Andreas Meisel   +14 more
wiley   +1 more source